There are few clinical data on the sequential use of aromatase inhibitors (AI). This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR). who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ).
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Data di pubblicazione: | 2001 | |
Titolo: | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? | |
Autori: | Carlini, P; Frassoldati, Antonio; De Marco, S; Casali, A; Ruggeri, E. M; Nardi, M; Papaldo, P; Fabi, A; Paoloni, F; Cognetti, F. | |
Rivista: | ANNALS OF ONCOLOGY | |
Parole Chiave: | Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles; Aromatase Inhibitors | |
Abstract: | There are few clinical data on the sequential use of aromatase inhibitors (AI). This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR). who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ). | |
Digital Object Identifier (DOI): | 10.1023/A:1013180214359 | |
Handle: | http://hdl.handle.net/11392/2377871 | |
Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.